<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR15">
 <label>15.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Chauffert</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Mornex</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Bonnetain</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Rougier</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Mariette</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Bouche</surname>
    <given-names>O</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study</article-title>
  <source>Ann Oncol</source>
  <year>2008</year>
  <volume>19</volume>
  <issue>9</issue>
  <fpage>1592</fpage>
  <lpage>1599</lpage>
  <pub-id pub-id-type="doi">10.1093/annonc/mdn281</pub-id>
  <pub-id pub-id-type="pmid">18467316</pub-id>
 </element-citation>
</ref>
